Essex Management, an Emmes Group company, has appointed David Loose as Chief Executive Officer (CEO), effective immediately.

Increases speed to market for drug developers working on nucleic acid therapeutics.

Galapagos plans to discontinue its small molecule discovery programs and seek potential partners to take over these assets, ...

The companies entered the agreement in 2023 to jointly advance as many as 11 drug programs, mainly targeting cardiovascular ...

Mytos, a provider of automated cell manufacturing, has entered a manufacturing collaboration with Aspen Neuroscience, Inc. to ...